Why Is TWIST BIOSCIENCE COR (TWST) Stock Up Today?

TWST stock is up 20.51% at $139.91 as of the latest trade, driven by news that Twist Bioscience is assisting Anthropic in testing whether its AI model, Claude, can accelerate the drug-design process. The stock opened with a 3.1% gap up and reached a session high of $141.10 before settling near $139.91. The move reflects investor optimism about the company's role in AI-driven biotech innovation.

What Happened

Twist Bioscience disclosed through an SEC Form 8-K filing that it is an independent evaluator for Anthropic, testing the AI model's ability to design proteins that bind to drug targets. The company successfully validated 14 of 15 targets in the test, a result that has drawn attention from both the biotech and AI sectors. This development comes after Anthropic announced the collaboration publicly, sparking a broader market reaction that also lifted AI-linked biotech peers. The stock is now trading at its highest level since 2021 and has hit a 52-week high for the first time on August 19.

What The Data Shows

The stock opened at $119.75 and has traded in a wide range, reaching a high of $141.10. Volume has surged to 2.2 million shares, which is 1.3 times the 3-month daily average. Over the past 8 sessions, the stock has gained 2.8%, moving from $112.95 to $116.10 before today’s surge. The 52-week range is $23.30 to $126.40, and the stock is now well above its previous peak. Meanwhile, insiders have sold a total of $34.4 million worth of shares in the last 90 days, with the most recent transaction on August 14.

What To Watch

Twist Bioscience is not scheduled to report earnings in the near term, but coverage breadth and investor sentiment will be key to watch. The stock’s recent performance suggests strong momentum, but its fundamentals remain unprofitable with a net margin of -31.7%.